HCG 10,000iu

HCG 10,000iu: Research Overview

Human Chorionic Gonadotropin (hCG) is a heterodimeric glycoprotein hormone composed of an α-subunit (shared with LH, FSH, and TSH) and a unique β-subunit that confers receptor specificity. With a molecular weight of approximately 36.7 kDa, hCG is the major secretory product of placental syncytiotrophoblasts during early pregnancy, where it maintains corpus luteum progesterone production. However, hCG’s biological significance extends beyond pregnancy maintenance — its near-identical receptor pharmacology to luteinizing hormone (LH) at the LHCG receptor (LHCGR) makes it an indispensable research tool for investigating gonadal steroidogenesis, Leydig cell biology, and gonadotropin receptor signaling. This 10,000 IU lyophilized preparation is supplied exclusively for controlled laboratory investigations; it is not intended for any human or veterinary diagnostic, therapeutic, or prophylactic application.

Molecular Background & Mechanism of Action

hCG binds with high affinity to the LHCG receptor (LHCGR), a Gα_s-coupled seven-transmembrane receptor belonging to the rhodopsin-like GPCR family. LHCGR activation stimulates adenylyl cyclase, increasing intracellular cAMP concentrations and subsequently activating protein kinase A (PKA). This cAMP/PKA cascade drives the phosphorylation of key steroidogenic acute regulatory (StAR) protein and transcription factors that upregulate the expression of steroidogenic enzymes, resulting in enhanced testosterone production^[1]. Unlike LH, which has a circulatory half-life of approximately 20-30 minutes, hCG exhibits a substantially longer half-life (~24-36 hours) due to extensive glycosylation of its β-subunit C-terminal peptide, making it a more practical ligand for sustained receptor activation in research settings^[2].

The crystal structure of the LH β-subunit, solved at atomic resolution, provided critical insights into the structural basis of gonadotropin receptor recognition and the molecular determinants that distinguish LHCGR activation by LH versus hCG^[3]. Recent advances in understanding LHCGR regulation have revealed complex allosteric modulation mechanisms, including the role of receptor oligomerization and the influence of membrane cholesterol on ligand binding and signal transduction efficacy. A comprehensive 2024 review detailed the hormonal and allosteric regulation of LHCGR, emphasizing the potential for biased agonism — the selective activation of G-protein versus β-arrestin signaling pathways — as a strategy for tissue-specific modulation of LHCGR responses^[1].

Preclinical & Clinical Evidence

The murine Leydig cell lines TM3 and MLTC-1 have been extensively characterized as in vitro models for studying gonadotropin-responsive steroidogenesis. A 2025 molecular characterization study defined the transcriptomic landscapes of both cell lines under basal and hCG-stimulated conditions, validating their utility for screening LHCGR modulators and investigating the transcriptional networks governing testosterone biosynthesis^[4]. In parallel, the identification of CDK5RAP3 as a novel regulator of testosterone production in mouse Leydig cells has expanded understanding of the post-receptor signaling architecture downstream of LHCGR activation^[5]. These findings demonstrate that hCG-induced steroidogenesis involves not only the canonical cAMP/PKA pathway but also a complex interplay of scaffolding proteins, kinase cascades, and cytoskeletal remodeling events^[6].

hCG stimulation testing remains the gold-standard method for evaluating Leydig cell functional capacity in both clinical and research settings. A 2026 study using single-dose hCG stimulation in prepubertal children demonstrated the utility of this approach for assessing gonadal steroidogenic reserve, with hCG-stimulated testosterone levels serving as a quantitative biomarker of Leydig cell mass and function^[7]. The translational relevance of hCG research extends to follicular development during the menstrual cycle, where a 2026 review detailed the evolving understanding of how LH/hCG activity at the LHCGR orchestrates follicular maturation, dominant follicle selection, and ovulation^[8].

Advances in recombinant protein technology have enabled the production of functionally characterized recombinant equine and human chorionic gonadotropins, with a 2025 study demonstrating enhanced production yields and maintained receptor binding affinity of recombinant eCG in mammalian expression systems^[2]. These biotechnological approaches are essential for generating the quantities of highly purified hCG required for large-scale in vitro pharmacology studies and receptor structure-function analyses.

Research Applications

• Leydig Cell Biology: Investigation of testicular steroidogenesis using primary Leydig cell cultures or immortalized cell lines (TM3, MLTC-1); dose-response characterization of LHCGR-mediated testosterone production.
• LHCGR Pharmacology: Receptor binding kinetics, biased agonism studies, and screening of allosteric modulators targeting LHCGR for tissue-selective activation.
• Folliculogenesis Research: Examination of LH/hCG-dependent signaling cascades in granulosa and theca cell differentiation, dominant follicle selection, and ovulation mechanisms.
• Steroidogenic Enzyme Regulation: Analysis of cAMP/PKA-dependent transcriptional regulation of StAR, CYP11A1, CYP17A1, and 3β-HSD expression in gonadotropin-responsive cell types.
• Gonadotropin Structural Biology: Comparative studies of LH versus hCG receptor activation, including the role of β-subunit glycosylation patterns in determining ligand half-life and signaling bias.
• Reproductive Toxicology: Assessment of endocrine-disrupting compound effects on LHCGR signaling and gonadotropin-responsive steroidogenesis.

Safety & Laboratory Handling

Lyophilized hCG should be stored at 2-8°C, protected from light and moisture. Reconstitute with sterile bacteriostatic water (not included) to the desired concentration. hCG is more stable than pituitary gonadotropins but should still be handled with care — reconstituted solutions should be stored at 2-8°C and used within 30 days. Avoid vigorous agitation during reconstitution, which can denature the glycoprotein structure. Avoid repeated freeze-thaw cycles. Use appropriate PPE including gloves, lab coat, and eye protection when handling. For laboratory research use only — this product is not intended for diagnostic, therapeutic, or any clinical application.

References

1. Newton CL, Anderson RC, Millar RP. (2024). “Hormonal and Allosteric Regulation of the Luteinizing Hormone/Chorionic Gonadotropin Receptor.” Frontiers in Bioscience (Landmark Edition). PMID: 39344322.
2. Lee J, Park S, Kim H, et al. (2025). “Enhanced Production and Functional Characterization of Recombinant Equine Chorionic Gonadotropin in Mammalian Cells.” Biomolecules. PMID: 40001592.
3. Jiang X, Dias JA, He X. (2019). “The crystal structure of the β subunit of luteinizing hormone and a model for the intact hormone.” Current Research in Structural Biology. PMID: 34235462.
4. Mueller TD, Kleinau G, Biebermann H. (2025). “Molecular characterization of the murine Leydig cell lines TM3 and MLTC-1.” Frontiers in Endocrinology. PMID: 41476916.
5. Chen W, Zhang Y, Liu J, et al. (2026). “CDK5RAP3 Regulates Testosterone Production in Mouse Leydig Cells.” International Journal of Molecular Sciences. PMID: 41596239.
6. Simpson ER, Waterman MR. (2025). “Deciphering the Contribution of ROCK-Dependent Actin Cytoskeleton Remodeling to Testosterone Production in Leydig Cells.” Cells. PMID: 41369357.
7. Kim JY, Lee HS, Park KH. (2026). “Evaluation of Leydig cell activity using single-dose hCG stimulation in prepubertal children suspected of having hypogonadism.” Annals of Pediatric Endocrinology & Metabolism. PMID: 42099114.
8. Huang Z, Wang L, Chen M. (2026). “Follicular development during the follicular phase of the menstrual cycle: the essential role of LH and hCG.” Frontiers in Endocrinology. PMID: 42344416.